What's in Rose Research Center, LLC's pipeline?

Rose Research Center, LLC has 2 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Rose Research Center, LLC's portfolio?

Top competitors by shared drug class: Eisai Korea Inc., Mario Negri Institute for Pharmacological Research.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/rose-research-center-llc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Rose Research Center, LLC — Portfolio Competitive Intelligence Brief

Rose Research Center, LLC pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Hydroxyzine Pill	Hydroxyzine Pill	marketed
Placebo zonisamide	Placebo zonisamide	phase 3	Sulfonamide anticonvulsant	Voltage-sensitive sodium channels	Neurology

Therapeutic area mix

Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Eisai Korea Inc. · 1 shared drug class
Mario Negri Institute for Pharmacological Research · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Rose Research Center, LLC:

Cite this brief

Drug Landscape (2026). Rose Research Center, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/rose-research-center-llc. Accessed 2026-05-16.